Vanguard Group’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Vanguard Group’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-994,997	Closed	-$1.8M	–	4589
2023 Q2	$1.8M	Sell	994,997 -140,552	-12%	-$257K	﹤0.01%	3700
2023 Q1	$1.5M	Buy	1,135,549 +5,358	+0.5%	+$8.76K	﹤0.01%	3782
2022 Q4	$1.91M	Buy	1,130,191 +6,333	+0.6%	+$8.02K	﹤0.01%	3672
2022 Q3	$2.08M	Buy	1,123,858 +21,824	+2%	+$65.1K	﹤0.01%	3726
2022 Q2	$3.38M	Buy	1,102,034 +116,060	+12%	+$709K	﹤0.01%	3568
2022 Q1	$7.12M	Buy	+985,974	New	+$9.7M	﹤0.01%	3329

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Vanguard Group's PRDS Position: Q3 2023 in Review

Vanguard Group sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 994,997 shares — an estimated $1.8M sold.

Vanguard Group first reported a position in PRDS in Q1 2022 and held it in 6 quarters. The position peaked at $7.12M in Q1 2022. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Vanguard Group reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Vanguard Group sold 994,997 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $1.8M.
Vanguard Group first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
Vanguard Group's Pardes Biosciences, Inc. Common Stock position peaked at $7.12M in Q1 2022.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Vanguard Group's 13F filing for Q3 2023, filed 14 Nov 2023.